Search

The article presents several studies presented on the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy on issues on HIV therapeutics. It notes that conference highlighted findings that can be beneficial in making decisions such as when to begin antiretroviral therapy and suitable therapies for antiretroviral-naive patients. It also relates current developments in antiretroviral therapies which are in phase 1 and 2 which include the oral drug bevirimat and elvucitabine.

Information on the new insights in Human Immunodeficiency Virus (HIV) treatments discussed at the 17th International AIDS Conference in Mexico City, Mexico on August 3-8, 2008 is presented. Topics include the encouragement for antiretroviral treatment as HIV preventive measures, and several researches that examined the clinical efficacy and safety of Nucleoside Reverse Transcriptase Inhibitors (NDTI). It also presents the limitations of the antiretroviral and its risk factors.

The article presents the summary of the key studies discussed during the 15th Conference on Retroviruses and Opportunistic Infections held on February 3-6, 2008 in Boston, Massachusetts. It explores several trials of previous studies and studies on therapies for initial treatment and therapies for treatment-experienced patients. Moreover, it also explores the studies on the effectiveness and safety of the three recently approved therapy agents including etravirine, raltegravir and maravinoc.

Information about the topics discussed at the Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention on July 22-25, 2007 in Sydney, New South Wales is presented. It discussed medical advancements to alleviate and prevent HIV infections. It provided preliminary support for several new concepts in HIV therapeutics that clinicians should consider. It presented the usage of HLA-B*5701 testing that significantly reduce the incidence of abacavir allergy.

The article discusses the advances in human immunodeficiency virus (HIV) therapeutics in the U.S. Based on the addition of several new antiviral treatment options in 2006, the potential for successful management of treatment-experienced patients has been improved. These include the Food and Drug Administration (FDA)-approved darunavir (DRV) and three drugs in expanded access.

The article presents news concerning developments in HIV therapeutics. The International AIDS Society (IAS)-USA panel recommends efavirenz as the initial NNRTI in antiretroviral-naive patients. The IAS-USA recommendations list multiple ritonavir-boosted protease inhibitors as recommended or preferred for antiretroviral-naive patients. Fixed-dose and coformulated NRTIs are listed in medical guidelines as initial therapies of choice.

Information about several issues discussed at the XVI International AIDS Conference is presented. A study on potential risks of treatment strategies interruption on HIV/AIDS prevention is discussed. Likewise, the conference featured various AIDS clinical trials presentation including the use of Lopinavir/Ritonavir as a single-drug therapy.

Information about the XVI International AIDS Conference which was held in Toronto, Ontario on August 13-18, 2006 is presented. More than 25,000 researchers, health care providers, patient advocates, and patients attended the biannual event. Prevention of communicable diseases was the focus of the conference.

The article provides studies on the effect of antiretroviral therapy on cardiovascular disease presented during the 2009 Conference on Retroviruses and Opportunistic Infections in Quebec. The Data Collection on Adverse Events of Anti-HIV Drugs study shows individual agents associated with the risk of myocardial infarction. The Women's Interagency HIV Study and the Multicenter AIDS Cohort Study uphold that there is no association between abacavir and elevated levels of the inflammatory markers.